JSKN022 / Alphamab - LARVOL DELTA

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN022 in Subjects with Advanced Malignant Solid Tumors (ChiCTR) - P1 | N=225 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

New P1 trial • Oncology • Solid Tumor

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022 (Alphamab Press Release) - "JSKN022-101 is an open-label, multi-center, phase I clinical trial of JSKN022, including dose-escalating and dose-optimization phases. This study aims to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD), and antitumor activity of JSKN022 in patients with advanced malignant solid tumors..."

Trial status • Solid Tumor

JSKN022:..Expected Milestones in 2025 (PRNewswire-Asia) - "The first patient will be dosed in the Chinese phase I clinical study of JSKN022 in patients with advanced malignant solid tumors who have failed standard therapies."

New P1 trial • Solid Tumor

IND APPLICATION FOR JSKN022 WAS OFFICIALLY ACCEPTED BY THE CDE (HKEXnews) - "The board (the 'Board') of directors (the 'Directors') of the Company is pleased to announce that the Investigational New Drug (the 'IND') application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate ('ADC') targeting programmed death ligand 1 ('PD-L1') and integrin αvβ6, has been officially accepted by the Center for Drug Evaluation (the 'CDE') of the National Medical Products Administration of China (the 'NMPA'). The Company plans to initiate a first-in-human clinical study of JSKN022 for the treatment of advanced malignant solid tumors."

New trial • Solid Tumor

JSKN022, a first in class multi-specific ADC targeting PD-L1 and ITGB6/8 with an innovative DNA topoisomerase I inhibitor demonstrates encouraging efficacy in preclinical models (AACR 2025) - "This preclinical study suggests JSKN022, as a first in class multi-specific PD-L1/ITGB6/8 ADC, might potentially bring in novelty in the therapeutic approach for cancers that are refractory or resistant to PD-1/PD-L1 inhibitors."

IO biomarker • Preclinical • Oncology • ITGB6